AGREEMENT ON ASSIGNMENT ANDCOMPENSATION FOR INVENTIONS
Contract Categories:
Business Finance
- Assignment Agreements
EX-10.1 2 v157193_ex10-1.htm Unassociated Document
Exhibit 10.1
AGREEMENT ON ASSIGNMENT AND COMPENSATION FOR INVENTIONS
THIS AGREEMENT, effective July 2, 2008, is by and between The Quigley Corporation, a corporation of the State of Pennsylvania, having a principal place of business at Kells Building, 621 Shady Retreat Road, Doylestown, Pennsylvania ###-###-####, United States of America, (hereinafter "Quigley") and Dr. Richard Rosenbloom, a citizen of the United States of America, residing at 1416 Tanglewood Drive, North Wales, Pennsylvania, 19454, United States of America (hereinafter "Dr. Rosenbloom").
WHEREAS Dr. Rosenbloom had certain concepts and/or inventions prior to the date of him becoming an employee of The Quigley Corporation.
WHEREAS Quigley desires to obtain entire right, title and interest in and to the Rosenbloom concepts and/or inventions and to pursue such concepts and/or inventions through investment and the work of Dr. Rosenbloom, and in and to any patent applications and patents relating to the subject matter of such concepts and/or inventions in any and all countries.
WHEREAS Dr. Rosenbloom assigned the entire right, title and interest in and to said concepts and/or inventions, and in and to any patent applications and patents relating to the subject matter of said inventions in any and all countries by virtue of executed assignment documents.
WHEREAS Quigley agreed to compensate Dr. Rosenbloom for assigning the entire right, title and interest into Dr. Rosenbloom's concepts and/or inventions made prior to the date he became an employee of Quigley.
WHEREAS Quigley has made a substantial investment of capital, labor and other resources into the development of the concepts and/or inventions made by Dr. Rosenbloom while an employee of Quigley, as well as patenting the inventions during the period of his employment by Quigley.
THEREFORE, the parties agree as follows:
ARTICLE I - - DEFINITIONS
1.0 | Quigley and Dr. Rosenbloom are hereunder commonly reviewed to as "parties" (in singular and plural usage, as required by the context. |
1.1 | Terms in this agreement (other than the name of the parties and Article headings) which are set forth in upper case letters have the meanings established for such terms in the succeeding paragraphs of this ARTICLE I. |
1.2 | INVENTIONS made by Dr. Rosenbloom prior to or after the date of his employment by Quigley, which are specifically set forth in Exhibit A hereto. |
1.3 | PATENTS means the patents listed in Exhibit A hereto, as well as any patent granted on the basis of any patent application listed in Exhibit A hereto, or which claims priority to any patent application listed in Exhibit A hereto under the relevant provisions of the Paris Convention, as well as reexaminations and reissues thereof which may be granted upon said application and upon any and all continuation or divisional applications for patents for said inventions, in and for the United States and foreign countries. |
1.4 | ROYALTY-BEARING PRODUCT means any product which embodies one or more of the INVENTIONS and comes within the scope of any unexpired claim of any of the PATENTS. |
1.5 | LICENSING COSTS means costs incurred by Quigley to obtain any licenses from third parties necessary to make, use, sell or offer to sell ROYALTY- BEARING PRODUCTS. |
1.6 | TITLE DEFENSE COSTS means costs incurred by Quigley to defend its title to the INVENTIONS, any patent applications for protection of the INVENTIONS, and/or any PATENTS from any challenge to Quigley's title made by a third party. |
1.7 | NET SALES, according to Generally Accepted Accounting Principles (GAAP), in respect to ROYALTY-BEARING PRODUCTS sold means amounts actually collected after deduction of certain items, such as, but is not limited to, regular trade and quantity discounts, returns and allowances, co-operative incentives, less LICENSING COSTS and TITLE DEFENSE COSTS. |
ARTICLE II - REPRESENTATIONS, WARRANTIES AND LIMITATIONS
2.1 | Dr. Rosenbloom represents and warrants in respect to the PATENTS that Dr. Rosenbloom has the legal right to extend the rights granted to Quigley in this agreement and in the assignment agreements, which agreements are incorporated by reference, and that Dr. Rosenbloom has not made and will not make any commitments to others inconsistent with or in derogation of such rights. |
2.2 | Dr. Rosenbloom represents and warrants that Dr. Rosenbloom has not published, caused to be published, publicly used or disclosed, caused to be publicly used or disclosed, offered for sale or caused to be offered for sale, any of the INVENTIONS prior to the date of filing of the first United States patent application which discloses the respective one of the INVENTIONS. |
2.3 | Dr. Rosenbloom represents and warrants that he is the original, first and sole inventor of each of the INVENTIONS. |
2.4 | Dr. Rosenbloom represents and warrants that he has disclosed to Quigley all information in his possession pertaining to the INVENTIONS which may be necessary or useful for the preparation and filing of patent applications for the protection of such INVENTIONS, which may be required for the patent applicant to satisfy its duty of disclosure to any of the patent offices in which a patent application for protection of any of said INVENTIONS is filed, and which may be required to determine ownership of said INVENTIONS under the applicable law. |
2.5 | Dr. Rosenbloom represents and warrants that he has been advised of his right to have this agreement reviewed by independent counsel of his own choosing and that he has, in fact, had this agreement reviewed by independent counsel or has freely chosen to waive this right. |
2.6 | Dr. Rosenbloom represents and warrants that he has not relied on any representations made by counsel for Quigley in entering into this agreement. |
2.7 | Nothing in this agreement shall be construed as: |
(a) A requirement that either party shall file any patent application(s), secure any patent(s), or maintain any patent(s) in force, | |
(b) An obligation to bring or prosecute actions or suits against third parties for infringement of any patent, or | |
(c) Granting by implication, estoppel or otherwise, any licenses or rights under any patents other than PATENTS. |
ARTICLE III - FILING AND PROSECUTION OF APPLICATIONS
3.1 | Dr. Rosenbloom shall, from time to time, on request, supply such additional information as may be necessary or desirable to facilitate prosecution of patent applications for the protection of the INVENTIONS. |
3.2 | Dr. Rosenbloom shall, each time a request is made and without undue delay, execute and deliver such papers as may be necessary or desirable to perfect the title to the INVENTIONS, and any patent applications or PATENTS to Quigley, its successors, assigns, nominees or legal representatives. |
3.3 | Dr. Rosenbloom shall testify in any legal proceedings, sign all lawful papers, execute all disclaimers and divisional, continuing, reissue and foreign applications, make all rightful oaths, and generally do everything possible to aid Quigley, its successors, assigns, nominees or legal representatives, to obtain and enforce, for its or their own benefit, proper patent protection for the INVENTIONS in any and all countries. |
3.4 | Quigley will accept financial responsibility for: |
(a) | Preparation, by a patent lawyer in independent practice who shall be nominated by Quigley, of a patent application or applications on patentable aspects of the INVENTIONS, |
(b) | Filing, upon execution by Dr. Rosenbloom, of such patent application or applications, and |
(c) | Prosecution by such nominated lawyer of the application or applications. |
3.5 | Quigley may, at any time, decide not to file a patent application, decide not to further prosecute a patent application, or decide not to maintain a patent, at its own discretion. |
ARTICLE IV - ASSIGNMENT OF RIGHTS
4.1 | Dr. Rosenbloom shall assign all right, title and interest in and to said INVENTIONS, and in and to any patent applications for protection of said INVENTIONS, including the right to claim priority to the patent applications in any foreign patent application entitled to claim such priority under national law, international conventions, treaties or otherwise, and any and all continuations, divisions, and renewals of, and substitutes for, said applications, and in, to and under any and all patents which may be granted on or as a result of said patent applications in any and all countries, and any reissue or reissues, or extension or extensions of said patents, and authorize Quigley to file in Dr. Rosenbloom's name, applications for patents in all countries, the same to be held and enjoyed by Quigley, its successors, assigns, nominees or legal representatives, to the full end of the term or terms for which said patents, respectively, may be granted, reissued or extended, as fully and entirely as the same would have been held and enjoyed by me had this assignment, sale and transfer not been made. |
4.2 | Quigley shall have the right to bring suit in its own name, or, if required by law, jointly with Dr. Rosenbloom, at its own expense and on its own behalf, for infringement of the PATENTS. In any such suit, Quigley shall have the right to enjoin for infringement and to collect for its use, damages, profits, and awards of whatever nature recoverable for such infringement, and to settle any claim or suit for infringement of the PATENTS by granting the infringing party a license under one or more of the PATENTS. Quigley shall pay to Dr. Rosenbloom five percent (5%) of the excess of any recoveries over expenses in such suits. |
ARTICLE V - - COMPENSATION AND REPORTS
5.1 | In consideration of, and as full compensation for, the covenants made in this agreement, Quigley shall pay to Dr. Rosenbloom compensation in the amount of five percent (5%) of NET SALES, of ROYALTY-BEARING PRODUCTS. |
5.2 | Quigley shall pay compensation to Dr. Rosenbloom biannually, and shall have thirty (30) days from the end of each six-month compensation period to pay the compensation to Dr. Rosenbloom and provide the report specified in paragraph 5.4 of this agreement. As long as Dr. Rosenbloom is an employee of The Quigley Corporation, The Quigley Corporation shall withhold all applicable and appropriate federal, state and local taxes. |
5.3 | Quigley shall pay to Dr. Rosenbloom five percent (5%) of any Royalty-Bearing License other than a license to a joint venture or a partnership. Quigley shall have the sole discretion to determine the terms of the license. If a Royalty-Bearing License is sold by The Quigley Corporation and consideration paid to Dr. Rosenbloom under this paragraph, there shall be no further obligation to pay royalties under Article V. |
5.4 | Quigley shall provide a report to Dr. Rosenbloom, along with the compensation set forth in paragraph 5.1 above, which includes sufficient information to verify the correctness of the amount of compensation provided to Dr. Rosenbloom for the previous six-month period. |
5.5 | Dr. Rosenbloom shall have the right at his expense to audit annually the books and records relating to the computation of this consideration paid to him under this article. |
ARTICLE VI - TRANSFER OF RIGHTS AND OBLIGATIONS
6.1 | The rights and obligations of Quigley under this agreement shall pass to any assigns for the benefit of creditors of Quigley, and to any receiver of Quigley's assets, or to any person or corporation succeeding to Quigley's entire business as a result of sale, consolidation, reorganization or otherwise, provided such assignee, receiver, person or legal entity shall, without delay, accept in writing the provisions of this agreement, and agree in all respects to be bound thereby in the place and stead of Quigley. |
6.2 | Quigley may assign the rights and obligations to any person or legal entity, provided such assignee, receiver, person or legal entity shall, without delay, accept in writing the provisions of this agreement, and agree in all respects to be bound thereby in the place and stead of Quigley. |
ARTICLE VII - TERM AND TERMINATION
7.1 | This agreement may only be terminated in the event of a material breach by either party in the due observance or performance of any covenant, condition or limitation of this agreement, but only if such material breach has not been remedied within thirty (30) days after receipt from the non-breaching party of written notice of such material breach. |
7.2 | If, in any proceeding in which the validity, infringement, ownership or priority of invention of any claim of any PATENT is in issue, a judgment or decree is entered which becomes not further renewable through the exhaustion of all |
permissible applications for rehearing or review by a superior tribunal, or through the expiration of the time permitted for such applications (hereinafter referred to as "an irrevocable judgment"), the construction placed upon any such claim by such irrevocable judgment shall thereafter be followed, not only as to such claims but as to all claims to which such construction applies, with respect to acts occurring thereafter, and, if such irrevocable judgment holds any claim invalid or is adverse to the patent as to inventorship or ownership, Quigley shall be relieved from including in its reports, products sold covered only by such claim or by any broader claim to which such irrevocable judgment is applicable, and from the performance of those other acts which may be required by this agreement only because of any such claim: provided however, that if there are two or more conflicting irrevocable judgments with respect to the same claim, the decision of the higher tribunal shall be followed thereafter, but if the tribunals be of equal dignity, the decision more favorable to the claim shall be followed until the less favorable decision has been followed by the irrevocable judgment of a tribunal of at least equal dignity. In the event of conflicting irrevocable judgments by the same court, the latest judgment shall control.
ARTICLE VIII - NOTICES, APPLICABLE LAW, ARBITRATION
8.1 | Any notice, report or payment provided for in this agreement shall be deemed sufficiently given when sent by certified or registered mail address to the party for whom intended at the address given at the outset of this agreement or at such changed address as the party shall have specified by written notice. |
8.2 | This agreement shall be construed, interpreted, and applied in accordance with the laws of the Commonwealth of Pennsylvania. |
8.3 | Any controversy or claim arising under or related to this agreement shall be settled by arbitration in accordance with the applicable arbitration rules of the American Arbitration Association before a single arbitrator selected in accordance with those rules, and judgment upon the award rendered by the arbitrator may be entered in any court having jurisdiction thereof. |
ARTICLE IX - INTEGRATION
9.1 | This instrument, and the Exhibit A hereto, contain the entire agreement between the parties and supersedes all preexisting oral agreements and any other written agreements, other than Assignment Agreements, respecting the subject matter of this agreement Any representation, promise, or condition in connection with such subject matter which is not incorporated in this agreement shall not be binding upon either party. No modification, renewal, extension, waiver, or termination shall be binding upon the party against whom the enforcement of such modification, renewal, extension, waiver or termination is sought, unless made in writing and signed on behalf of such party. |
IN WITNESS WHEREOF, each of the parties intending to be legally bound hereby has caused this agreement to be executed and duly sealed in duplicate originals.
The Quigley Corporation | |||||
By | /s/ Guy J. Quigley | /s/ Richard Rosenbloom | |||
Guy J. Quigley, President | Dr. Richard Rosenbloom | ||||
| |||||
Attest: | |||||
/s/ Charles Phillips | | ||||
Charles Phillips, Secretary |
QUIG REF. | MATTER NO. | TITLE | SERIAL NO. | FILE DATE | PATENT NO. | ISSUE DATE | STATUS | EXPIRATION |
QR-333 | QUIG-1001US | METHOD AND COMPOSITION FOR THE TOPICAL TREATMENT OF DIABETIC NEUROPATHY | 09/740,811 | 12/21/2000 | 6,555,573 | 4/29/2003 | ISSUED | 3/27/2021 |
QR-333 | QUIG-1001USDIV1 | METHOD AND COMPOSITION FOR THE TOPICAL TREATMENT OF DIABETIC NEUROPATHY | 10/369,025 | 2 /19/2003 | PUBLISHED | 12/21/2020 | ||
QR-333 | QUIG-1001AU | METHOD AND COMPOSITION FOR THE TOPICAL TREATMENT OF DIABETIC NEUROPATHY | 2002231095 | 12/19/2001 | 2002231095 | 11/24/2005 | ISSUED | 12/19/2021 |
QR-333 | QUIG-1001CA | METHOD AND COMPOSITION FOR THE TOPICAL TREATMENT OF DIABETIC NEUROPATHY | 2,431,079 | 12/19/2001 | PENDING | 12/19/2021 | ||
QR-333 | QUIG-1001EP | METHOD AND COMPOSITION FOR THE TOPICAL TREATMENT OF DIABETIC NEUROPATHY | 01991367.2 | 12/19/2001 | PUBLISHED | 12/19/2021 | ||
QR-333 | QUIG-1001IL | METHOD AND COMPOSITION FOR THE TOPICAL TREATMENT OF DIABETIC NEUROPATHY | 156549 | 12/19/2001 | PENDING | 12/19/2021 | ||
QR-333 | QUIG-1001IN | METHOD AND COMPOSITION FOR THE TOPICAL TREATMENT OF DIABETIC NEUROPATHY | 00870/DELNP/2003 | 12/19/2001 | PENDING | 12/19/2021 | ||
QR-333 | QUIG-1001JP | METHOD AND COMPOSITION FOR THE TOPICAL TREATMENT OF DIABETIC NEUROPATHY | 2002-550919 | 12/19/2001 | PENDING | 12/19/2021 | ||
QR-333 | QUIG-1001MX | METHOD AND COMPOSITION FOR THE TOPICAL TREATMENT OF DIABETIC NEUROPATHY | PA/A/2003/005672 | 12/19/2001 | 236311 | 4/28/2006 | ISSUED | 12/19/2021 |
QR-333 | QUIG-1001NZ | METHOD AND COMPOSITION FOR THE TOPICAL TREATMENT OF DIABETIC NEUROPATHY | 526041 | 12/19/2001 | 526041 | 5/12/2005 | ISSUED | 12/19/2021 |
QR-333 | QUIG-1001ZA | METHOD AND COMPOSITION FOR THE TOPICAL TREATMENT OF DIABETIC NEUROPATHY | 2003/4247 | 12/19/2001 | 2003/4247 | 7/28/2004 | ISSUED | 12/19/2021 |
QR-333 | QUIG-1011US | METHODS FOR THE TREATMENT OF PERIPHERAL NEURAL AND VASCULAR AILMENTS | 10/288,825 | 11/6 /2002 | 7,083,813 | 8/1/2006 | ISSUED | 8/4/2023 |
QR-333 | QUIG-1011USDIV1 | METHODS FOR THE TREATMENT OF PERIPHERAL NEURAL AND VASCULAR AILMENTS | 11/165,151 | 6 /23/2005 | PUBLISHED | 11/6/2022 | ||
QR-333 | QUIG-1011AU | METHODS FOR THE TREATMENT OF PERIPHERAL NEURAL AND VASCULAR AILMENTS | 2002352501 | 11/6 /2002 | 2002352501 | ISSUED | 11/6/2022 | |
QR-333 | QUIG-1011CA | METHODS FOR THE TREATMENT OF PERIPHERAL NEURAL AND VASCULAR AILMENTS | 2,470,603 | 11/6 /2002 | PENDING | 11/6/2022 | ||
QR-333 | QUIG-1011EP | METHODS FOR THE TREATMENT OF PERIPHERAL NEURAL AND VASCULAR AILMENTS | 02789474.0 | 11/6 /2002 | PUBLISHED | 11/6/2022 | ||
QR-333 | QUIG-1011IL | METHODS FOR THE TREATMENT OF PERIPHERAL NEURAL AND VASCULAR AILMENTS | 162505 | 11/6 /2002 | PENDING | 11/6/2022 | ||
QR-333 | QUIG-1011IN | METHODS FOR THE TREATMENT OF PERIPHERAL NEURAL AND VASCULAR AILMENTS | 1683/DELNP/2004 | 11/6 /2002 | PENDING | 11/6/2022 |
QUIG REF. | MATTER NO. | TITLE | SERIAL NO. | FILE DATE | PATENT NO. | ISSUE DATE | STATUS | EXPIRATION |
QR-333 | QUIG-1011JP | METHODS FOR THE TREATMENT OF PERIPHERAL NEURAL AND VASCULAR AILMENTS | 2003-554096 | 11/6 /2002 | PUBLISHED | 11/6/2022 | ||
QR-333 | QUIG-1011MX | METHODS FOR THE TREATMENT OF PERIPHERAL NEURAL AND VASCULAR AILMENTS | PA/A/2004/006039 | 11/6 /2002 | PENDING | 11/6/2022 | ||
QR-333 | QUIG-1011NZ | METHODS FOR THE TREATMENT OF PERIPHERAL NEURAL AND VASCULAR AILMENTS | 533439 | 11/6 /2002 | 533439 | 10/12/2006 | ISSUED | 11/6/2022 |
QR-333 | QUIG-1011TW | METHODS FOR THE TREATMENT OF PERIPHERAL NEURAL AND VASCULAR AILMENTS | 93102875 | 11/6 /2002 | PUBLISHED | 11/6/2022 | ||
QR-333 | QUIG-1011ZA | METHODS FOR THE TREATMENT OF PERIPHERAL NEURAL AND VASCULAR AILMENTS | 2004/4614 | 11/6 /2002 | 2004/4614 | 10/28/2005 | ISSUED | 11/6/2022 |
QR-334 | QUIG-1007US | MEDICAL COMPOSITION AND METHOD OF USING IT | 09/923,090 | 8 /6 /2001 | 6,592,896 | 7/15/2003 | ISSUED | 8/6/2021 |
QR-334 | QUIG-1007USCIP | NUTRITIONAL SUPPLEMENTS AND METHODS OF USING IT | 10/122,991 | 4 /15/2002 | 6,596,313 | 7/22/2003 | ISSUED | 8/6/2021 |
QR-334 | QUIG-1007AU | NUTRITIONAL SUPPLEMENTS AND METHODS OF USING IT | 2002332464 | 8 /6 /2002 | 2002332464 | 2/22/2007 | ISSUED | 8/6/2022 |
QR-334 | QUIG-1007CA | NUTRITIONAL SUPPLEMENT AND METHODS OF USING IT | 2,455,391 | 8 /6 /2002 | PENDING | 8/6/2022 | ||
QR-334 | QUIG-1007CN | NUTRITIONAL SUPPLEMENTS AND METHODS OF USING SAME | 02814148.2 | 8 /6 /2002 | PENDING | 8/6/2022 | ||
QR-334 | QUIG-1007IN | NUTRITIONAL SUPPLEMENT AND METHODS OF USING IT | 0004/MUMNP/2004 | 8 /6 /2002 | PENDING | 8/6/2022 | ||
QR-334 | QUIG-1007JP | NUTRITIONAL SUPPLEMENT AND METHODS OF USING IT | 2003-518442 | 8 /6 /2002 | PENDING | 8/6/2022 | ||
QR-334 | QUIG-1007IL | NUTRITIONAL SUPPLEMENTS AND METHODS OF USING SAME | 159357 | 8 /6 /2002 | 159357 | 11/21/2006 | ISSUED | 8/6/2022 |
QR-334 | QUIG-1007NZ | NUTRITIONAL SUPPLEMENT AND METHODS OF USING IT | 530187 | 8 /6 /2002 | PUBLISHED | 8/6/2022 | ||
QR-334 | QUIG-1007KR | NUTRITIONAL SUPPLEMENT AND METHODS OF USING IT | 10 ###-###-#### | 8 /6 /2002 | PENDING | 8/6/2022 | ||
QR-334 | QUIG-1007ZA | NUTRITIONAL SUPPLEMENT AND METHODS OF USING IT | 2003/9802 | 8 /6 /2002 | 2003/9802 | 7/28/2004 | ISSUED | 8/6/2022 |
QR-335 | QUIG-1006US | COMPOSITION AND METHOD FOR REDUCING RADIATION DERMATITIS | 09/993,003 | 11/6/2001 | 6,753,325 | 6/22/2004 | ISSUED | 11/6/2021 |
QUIG REF. | MATTER NO. | TITLE | SERIAL NO. | FILE DATE | PATENT NO. | ISSUE DATE | STATUS | EXPIRATION |
QR-335 | QUIG-06USCIP4 | TOPICAL COMPOSITIONS AND METHODS FOR TREATMENT OF ADVERSE EFFECTS OF IONIZING RADIATION | 10/288,761 | 11/6/2002 | PUBLISHED | 11/6/2021 | ||
QR-335 | QUIG-1006AU2 | TOPICAL COMPOSITIONS AND METHODS FOR TREATMENT OF ADVERSE EFFECTS OF IONIZING RADIATION | 2002365155 | 11/6/2002 | PENDING | 11/6/2022 | ||
QR-335 | QUIG-1006CA2 | TOPICAL COMPOSITIONS AND METHODS FOR TREATMENT OF ADVERSE EFFECTS OF IONIZING RADIATION | 2,465,888 | 11/6/2002 | PENDING | 11/6/2022 | ||
QR-335 | QUIG-1006CN2 | TOPICAL COMPOSITIONS AND METHODS FOR TREATMENT OF ADVERSE EFFECTS OF IONIZING RADIATION | 02826541.6 | 11/6/2002 | PUBLISHED | 11/6/2022 | ||
QR-335 | QUIG-1006EP2 | TOPICAL COMPOSITIONS AND METHODS FOR TREATMENT OF ADVERSE EFFECTS OF IONIZING RADIATION | 02803307.4 | 11/6/2002 | PUBLISHED | 11/6/2022 | ||
QR-335 | QUIG-1006HK2 | TOPICAL COMPOSITIONS AND METHODS FOR TREATMENT OF ADVERSE EFFECTS OF IONIZING RADIATION | 05111253.4 | 12/8/2005 | PUBLISHED | 12/8/2025 | ||
QR-335 | QUIG-1006IL2 | TOPICAL COMPOSITIONS AND METHODS FOR TREATMENT OF ADVERSE EFFECTS OF IONIZING RADIATION | 161775 | 11/6/2002 | PENDING | 11/6/2022 | ||
QR-335 | QUIG-1006IN2 | TOPICAL COMPOSITIONS AND METHODS FOR TREATMENT OF ADVERSE EFFECTS OF IONIZING RADIATION | 01160/DELNP/2004 | 11/6/2002 | PENDING | 11/6/2022 | ||
QR-335 | QUIG-1006JP2 | TOPICAL COMPOSITIONS AND METHODS FOR TREATMENT OF ADVERSE EFFECTS OF IONIZING RADIATION | 2003-552220 | 11/6/2002 | PUBLISHED | 11/6/2022 | ||
QR-335 | QUIG-1006MX2 | TOPICAL COMPOSITIONS AND METHODS FOR TREATMENT OF ADVERSE EFFECTS OF IONIZING RADIATION | PA/A/2004/004377 | 11/6/2002 | PUBLISHED | 11/6/2022 | ||
QR-335 | QUIG-1006NZ2 | TOPICAL COMPOSITIONS AND METHODS FOR TREATMENT OF ADVERSE EFFECTS OF IONIZING RADIATION | 532775 | 11/6/2002 | PUBLISHED | 11/6/2022 | ||
QR-335 | QUIG-1006ZA2 | TOPICAL COMPOSITIONS AND METHODS FOR TREATMENT OF ADVERSE EFFECTS OF IONIZING RADIATION | 2004/3365 | 11/6/2002 | 2004/3365 | 5/31/2006 | ISSUED | 11/6/2022 |
QR-336 | QUIG-1006USCIP | COMPOSITION FOR RADIATION DERMATITIS AND EXPOSURE | 10/045,790 | 1/14/2002 | PUBLISHED | |||
QR-336 | QUIG-1006AU | NUTRITIONAL SUPPLEMENTS AND METHODS FOR PREVENTION, REDUCTION AND TREATMENT OF RADIATION INJURY | 2002309615 | 5/1/2002 | PENDING | 5 /1 /2022 |
QUIG REF. | MATTER NO. | TITLE | SERIAL NO. | FILE DATE | PATENT NO. | ISSUE DATE | STATUS | EXPIRATION |
QR-336 | QUIG-1006CA | NUTRITIONAL SUPPLEMENTS AND METHODS FOR PREVENTION, REDUCTION AND TREATMENT OF RADIATION INJURY | 2,465,945 | 5/1/2002 | PENDING | 5 /1 /2022 | ||
QR-336 | QUIG-1006CN | NUTRITIONAL SUPPLEMENTS AND METHODS FOR PREVENTION, REDUCTION AND TREATMENT OF RADIATION INJURY | 02822057.9 | 5 /1 /2002 | PUBLISHED | 5 /1 /2022 | ||
QR-336 | QUIG-1006EP | NUTRITIONAL SUPPLEMENTS AND METHODS FOR PREVENTION, REDUCTION AND TREATMENT OF RADIATION INJURY | 02736624.4 | 5 /1 /2002 | PUBLISHED | 5 /1 /2022 | ||
QR-336 | QUIG-1006IL | NUTRITIONAL SUPPLEMENTS AND METHODS FOR PREVENTION, REDUCTION AND TREATMENT OF RADIATION INJURY | 161774 | 5 /1 /2002 | PENDING | 5 /1 /2022 | ||
QR-336 | QUIG-1006IN | NUTRITIONAL SUPPLEMENTS AND METHODS FOR PREVENTION, REDUCTION AND TREATMENT OF RADIATION INJURY | 01165/DELNP/2004 | 5 /1 /2002 | PENDING | 5 /1 /2022 | ||
QR-336 | QUIG-1006JP | NUTRITIONAL SUPPLEMENTS AND METHODS FOR PREVENTION, REDUCTION AND TREATMENT OF RADIATION INJURY | 2003-541744 | 5 /1 /2002 | PUBLISHED | 5 /1 /2022 | ||
QR-336 | QUIG-1006MX | NUTRITIONAL SUPPLEMENTS AND METHODS FOR PREVENTION, REDUCTION AND TREATMENT OF RADIATION INJURY | PA/A/2004/004376 | 5 /1 /2002 | PUBLISHED | 5 /1 /2022 | ||
QR-336 | QUIG-1006NZ | NUTRITIONAL SUPPLEMENTS AND METHODS FOR PREVENTION, REDUCTION AND TREATMENT OF RADIATION INJURY | 532774 | 5 /1 /2002 | PENDING | 5 /1 /2022 | ||
QR-336 | QUIG-1006ZA | NUTRITIONAL SUPPLEMENTS AND METHODS FOR PREVENTION, REDUCTION AND TREATMENT OF RADIATION INJURY | 2004/3364 | 5 /1 /2002 | PENDING | 5 /1 /2022 | ||
QR-433 | QUIG-07USDIV2 | COMPOSITIONS AND METHODS FOR TREATMENT OF RHINOVIRUS | 11/553,656 | 10/27/2006 | PENDING | 8 /6 /2021 | ||
QR-434 | QUIG-07USCON4 | COMPOSITIONS AND METHODS FOR TREATMENT OF HERPES | 11/371,974 | 3 /9 /2006 | 7,175,987 | 2 /13/2007 | ISSUED | 11/5 /2021 |
QR-435 | QUIG-07USCIP2 | ANTI-MICROBIAL COMPOSITIONS AND METHODS OF USING SAME | 10/359,889 | 2 /6 /2003 | PUBLISHED | 8 /6 /2021 | ||
QR-440 | QUIG-07USDIV1 | NUTRITIONAL SUPPLEMENTS AND METHODS OF USING SAME | 10/421,276 | 4 /23/2003 | 6,827,945 | 12/7 /2004 | ISSUED | 8 /6 /2021 |
QUIG REF. | MATTER NO. | TITLE | SERIAL NO. | FILE DATE | PATENT NO. | ISSUE DATE | STATUS | EXPIRATION |
QR-433-437 QR-439 QR-441-441(a) QR-444 QR-446 | QUIG-7USCIP3 | COMPOSITIONS AND METHODS FOR REDUCING THE TRANSMISSIVITY OF ILLNESSES | 11/012,764 | 12/14/2004 | 7,166,435 | 1 /23/2007 | ISSUED | 11/5 /2021 |
QR-433-437 QR-439 QR-441-441(a) QR-444 QR-446 | QUIG-1007AU2 | ANTI-MICROBIAL METHODS AND COMPOSITIONS | 2003256736 | 7 /24/2003 | PENDING | 7 /24/2023 | ||
QR-433-437 QR-439 QR-441-441(a) QR-444 QR-446 | QUIG-1007CA2 | ANTI-MICROBIAL METHODS AND COMPOSITIONS | 2,495,447 | 7 /24/2003 | PENDING | 7 /24/2023 | ||
QR-433-437 QR-439 QR-441-441(a) QR-444 QR-446 | QUIG-1007CN2 | ANTI-MICROBIAL METHODS AND COMPOSITIONS | 03818966.6 | 7 /24/2003 | PUBLISHED | 7 /24/2023 | ||
QR-433-437 QR-439 QR-441-441(a) QR-444 QR-446 | QUIG-1007EP2 | ANTI-MICROBIAL METHODS AND COMPOSITIONS | 03766897.7 | 7 /24/2003 | PUBLISHED | 7 /24/2023 | ||
QR-433-437 QR-439 QR-441-441(a) QR-444 QR-446 | QUIG-1007HK2 | ANTI-MICROBIAL METHODS AND COMPOSITIONS | 05112150.6 | 12/29/2005 | PUBLISHED | 12/29/2025 | ||
QR-433-437 QR-439 QR-441-441(a) QR-444 QR-446 | QUIG-1007IL2 | ANTI-MICROBIAL METHODS AND COMPOSITIONS | 166608 | 7 /24/2003 | PENDING | 7 /24/2023 | ||
QR-433-437 QR-439 QR-441-441(a) QR-444 QR-446 | QUIG-1007IN2 | ANTI-MICROBIAL METHODS AND COMPOSITIONS | 258/DELNP/2005 | 7 /24/2003 | PENDING | 7 /24/2023 | ||
QR-433-437 QR-439 QR-441-441(a) QR-444 QR-446 | QUIG-1007JP2 | ANTI-MICROBIAL METHODS AND COMPOSITIONS | 2004-526143 | 7 /24/2003 | PENDING | 7 /24/2023 |
QUIG REF. | MATTER NO. | TITLE | SERIAL NO. | FILE DATE | PATENT NO. | ISSUE DATE | STATUS | EXPIRATION |
QR-433-437 QR-439 QR-441-441(a) QR-444 QR-446 | QUIG-1007KR2 | ANTI-MICROBIAL METHODS AND COMPOSITIONS | 2005 ###-###-#### | 7 /24/2003 | PENDING | 7 /24/2023 | ||
QR-433-437 QR-439 QR-441-441(a) QR-444 QR-446 | QUIG-1007MX2 | ANTI-MICROBIAL METHODS AND COMPOSITIONS | PA/A/2005/001051 | 7 /24/2003 | PENDING | 7 /24/2023 | ||
QR-433-437 QR-439 QR-441-441(a) QR-444 QR-446 | QUIG-1007NZ2 | ANTI-MICROBIAL METHODS AND COMPOSITIONS | 537821 | 7 /24/2003 | PENDING | 7 /24/2023 | ||
QR-433-437 QR-439 QR-441-441(a) QR-444 QR-446 | QUIG-07WO3 | COMPOSITIONS AND METHODS FOR REDUCING THE TRANSMISSIVITY OF ILLNESSES | PCT/US2005/045218 | 12/14/2005 | PUBLISHED | |||
QR-433-437 QR-439 QR-441-441(a) QR-444 QR-446 | QUIG-1007ZA2 | ANTI-MICROBIAL METHODS AND COMPOSITIONS | 2005/0517 | 7 /24/2003 | 2005/0517 | 12/28/2005 | ISSUED | 7 /24/2023 |